Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lynn McFadyen

Showing results (1-10 of 34) with videos related to

Pageof 4
Sort By:
British Journal of Clinical Pharmacology|September 11, 2009
Maraviroc modelling strategy: use of early phase 1 data to support a semi-mechanistic population pharmacokinetic modelBarry Weatherley, Lynn McFadyen
Clinical and Translational Science|November 7, 2017
Population Pharmacokinetics of Fosdagrocorat (PF-04171327), a Dissociated Glucocorticoid Receptor Agonist, in Patients With Rheumatoid ArthritisBarry Weatherley, Lynn McFadyen, Brinda Tammara
Journal of Pharmacokinetics and Pharmacodynamics|March 6, 2010
Basic PK/PD principles of drug effects in circular/proliferative systems for disease modellingPhilippe Jacqmin, Lynn McFadyen, Janet R Wade
British Journal of Clinical Pharmacology|March 26, 2008
A receptor theory-based semimechanistic PD model for the CCR5 noncompetitive antagonist maravirocPhilippe Jacqmin, Lynn McFadyen, Janet R Wade
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 4, 2015
Clinical relevance of CYP3A5 genotype on maraviroc exposuresManoli Vourvahis, Lynn McFadyen, Jayvant Heera, et al.
British Journal of Clinical Pharmacology|March 26, 2008
A population pharmacokinetic meta-analysis of maraviroc in healthy volunteers and asymptomatic HIV-infected subjectsPhylinda L S Chan, Barry Weatherley, Lynn McFadyen
Contraception|January 15, 2004
Serum medroxyprogesterone acetate levels in new and repeat users of depot medroxyprogesterone acetate at the end of the dosing intervalJennifer Smit, Julia Botha, Lynn McFadyen, et al.
Social Science & Medicine (1982)|September 26, 2002
Vaginal wetness: an underestimated problem experienced by progestogen injectable contraceptive users in South AfricaJennifer Smit, Lynn McFadyen, Khangelani Zuma, et al.
African Journal of Reproductive Health|December 18, 2003
Dual protection against sexually transmitted infections and pregnancy in South AfricaChelsea Morroni, Jennifer Smit, Lynn McFadyen, et al.
Clinical Pharmacology and Therapeutics|December 6, 2020
Pregabalin Population Pharmacokinetic and Exposure-Response Analyses for Focal Onset Seizures in Children (4-16 years) and Adults, to Support Dose Recommendations in ChildrenPhylinda L S Chan, Scott F Marshall, Lynn McFadyen, et al.
Pageof 4

Showing results (1-10 of 34) with videos related to

Sort By:
Pageof 4
British Journal of Clinical Pharmacology|September 11, 2009
Maraviroc modelling strategy: use of early phase 1 data to support a semi-mechanistic population pharmacokinetic modelBarry Weatherley, Lynn McFadyen
Clinical and Translational Science|November 7, 2017
Population Pharmacokinetics of Fosdagrocorat (PF-04171327), a Dissociated Glucocorticoid Receptor Agonist, in Patients With Rheumatoid ArthritisBarry Weatherley, Lynn McFadyen, Brinda Tammara
Journal of Pharmacokinetics and Pharmacodynamics|March 6, 2010
Basic PK/PD principles of drug effects in circular/proliferative systems for disease modellingPhilippe Jacqmin, Lynn McFadyen, Janet R Wade
British Journal of Clinical Pharmacology|March 26, 2008
A receptor theory-based semimechanistic PD model for the CCR5 noncompetitive antagonist maravirocPhilippe Jacqmin, Lynn McFadyen, Janet R Wade
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 4, 2015
Clinical relevance of CYP3A5 genotype on maraviroc exposuresManoli Vourvahis, Lynn McFadyen, Jayvant Heera, et al.
British Journal of Clinical Pharmacology|March 26, 2008
A population pharmacokinetic meta-analysis of maraviroc in healthy volunteers and asymptomatic HIV-infected subjectsPhylinda L S Chan, Barry Weatherley, Lynn McFadyen
Contraception|January 15, 2004
Serum medroxyprogesterone acetate levels in new and repeat users of depot medroxyprogesterone acetate at the end of the dosing intervalJennifer Smit, Julia Botha, Lynn McFadyen, et al.
Social Science & Medicine (1982)|September 26, 2002
Vaginal wetness: an underestimated problem experienced by progestogen injectable contraceptive users in South AfricaJennifer Smit, Lynn McFadyen, Khangelani Zuma, et al.
African Journal of Reproductive Health|December 18, 2003
Dual protection against sexually transmitted infections and pregnancy in South AfricaChelsea Morroni, Jennifer Smit, Lynn McFadyen, et al.
Clinical Pharmacology and Therapeutics|December 6, 2020
Pregabalin Population Pharmacokinetic and Exposure-Response Analyses for Focal Onset Seizures in Children (4-16 years) and Adults, to Support Dose Recommendations in ChildrenPhylinda L S Chan, Scott F Marshall, Lynn McFadyen, et al.
Pageof 4